Brigimadlin (BI 907828), an oral MDM2–p53 antagonist (reactivates the tumor-suppressor function of p53 by inhibiting its interaction with MDM2, a protein amplified in 5%–8% of BTC cases), has demonstrated promising efficacy in phase 1a/2b trials. Here, TP53 is linked to neoplasm.